Diagnosis Value of SEMA4C in Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 2,300
- 主要终点
- Diagnostic potential of SEMA4C as a biomarker for breast cancer
研究概览
简要总结
Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.
详细描述
Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Early diagnosis and access to optimum treatment are crucial to reduce mortality associated with breast cancer. Currently, mammography and breast ultrasonography are essential for the detection and diagnosis of disease, and breast magnetic resonance imaging is the choice to estimate the extent of disease and guide appropriate treatment. However, there is no robust biomarkers for early detection of breast cancer.
Semaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. Therefore, this prospective project aims to assess the early diagnostic value of SEMA4C as a biomarker for breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Receiving no treatment before diagnosis
- •Establishing Diagnosis according to biopsy or surgery
排除标准
- •Patients who are not mentally capable of giving written informed consent
- •Clinical data missing
- •Serum samples doesn't qualified
- •Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results
结局指标
主要结局
Diagnostic potential of SEMA4C as a biomarker for breast cancer
时间窗: At the time of inclusion
Analyzing the predictive value of SEMA4C in the diagnosis of breast cancer.
次要结局
- Serum SEMA4C, Mammography, breast US and MRI in comparison and combination to distinguish breast cancer from benign breast tumor(At the time of inclusion)
研究者
Qinglei Gao
Clinical Professor
Tongji Hospital